Fred Alger Management, LLC Pliant Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$14.14 - $19.59 $349,328 - $483,970	-24,705 Reduced 20.29%	97,082 $1.45 Million
Q4 2023 Feb 14, 2024	BUY	$12.85 - $19.15 $74,298 - $110,725	5,782 Added 4.98%	121,787 $2.21 Million
Q3 2023 Nov 14, 2023	BUY	$14.58 - $20.15 $114,627 - $158,419	7,862 Added 7.27%	116,005 $2.01 Million
Q2 2023 Aug 14, 2023	SELL	$18.12 - $30.56 $17.5 Million - $29.6 Million	-968,492 Reduced 89.96%	108,143 $1.96 Million
Q1 2023 May 15, 2023	BUY	$18.73 - $36.26 $19.8 Million - $38.3 Million	1,056,584 Added 5269.48%	1,076,635 $28.6 Million
Q4 2022 Feb 14, 2023	SELL	$17.0 - $25.43 $106,556 - $159,395	-6,268 Reduced 23.82%	20,051 $387,000
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $201,866 - $637,709	26,319 New	26,319 $550,000

158

63.8M

481K

105K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $546M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.